[Characteristics and clinical efficacy of the sustained-release formulation of azalide azithromycin].
Shigeru
S
Kohno
D000208:Acute Disease; D000284:Administration, Oral; D017963:Azithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004304:Dosage Forms; D016503:Drug Delivery Systems; D004347:Drug Interactions; D024881:Drug Resistance, Bacterial; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008863:Microspheres; D017060:Patient Satisfaction; D016032:Randomized Controlled Trials as Topic; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects
D003692:Delayed-Action Preparations; D004304:Dosage Forms; D017963:Azithromycin